drugset / Trial / NCT00061802

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

NCT00061802

RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder

Timeline

Start
2003-06
Primary completion
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg
Subject Quetiapine Small molecule 600 mg
Subject Quetiapine Small molecule 800 mg
Subject Risperidone Other / unclassified 4 mg
Subject Risperidone Other / unclassified 6 mg